Rich is one of the co-founders of MTG and is President and Chief Executive Officer. He has also been a Board Member of MTG’s parent company in Japan, Momotaro-Gene Inc., since 2012 and has managed the development of REIC technology for the company since 2008. Prior to MTG, Rich was President of a rapidly growing biotechnology consulting firm, Pacific-Link Consulting Inc., in San Diego, CA. Rich has been a development and regulatory expert for over 25 years holding senior management positions at Cadence Pharmaceuticals, Maxim Pharmaceuticals, AnGes Inc., Janssen Research Foundation and Somerset Pharmaceuticals. Prior to his career in industry, Rich was a New Drug Reviewer for the US Food and Drug Administration in the Division of Oncology and the Division of Neuropharmacologic Drug Products.
Dr. Bell has supported the international pharmaceutical industry and academia for biological, drug and device development for over 30 years. His employment history includes Carter-Wallace, Inc., AL Pharma, UDL Laboratories, Inc., Somerset Pharmaceuticals, Inc. and Barr Laboratories, Inc. Dr. Bell is also an Adjunct Professor of Pharmaceutics at University of Florida, a member of the National Advisory Board and recipient of the Distinguished Alumnus Award at the College of Pharmacy at the University of Florida and Affiliate Faculty at the College of Pharmacy at Virginia Commonwealth University. Dr. Bell received his B.S. in Chemistry, M.S. in Food Science and Human Nutrition and Ph.D. in Pharmaceutics from the University of Florida.
Dr. Bell has published and presented extensively, and has been issued several patents. Research interests include pharmaceutical, clinical and biomedical analysis, CMC, quality, vaccines, FOP, women's heath and oncology therapeutics. Dr. Bell has served in various leadership capacities within the American Association of Pharmaceutical Scientists (AAPS) including Chair of the Analysis and Pharmaceutical Quality (APQ) section, Editorial Advisory Board for the Journal of Pharmaceutical and Biomedical Analysis, 2006 National Biotechnology Conference Chair and Member-At-Large. Dr. Bell is also a member of the American Society of Clinical Oncology, American Urology Association, International Society of Andrology, American Chemical Society, and American College of Pharmacology. Bell participates in the Visiting Scientist Program to universities, colleges and high schools.
Sarina joined MTG in 2014 as our first employee. She previously worked at Pacific-Link Consulting as Chief Medical Office in 2010 where she provided a range of development services to biotechnology and pharmaceutical companies including Momotaro-Gene, the parent company of MTG. Previously she served as Director of Business Development at AnGes MG where she contributed to licensing products and supporting their development through NDA filing and commercialization. Prior to taking a role in Business Development, Dr. Tanimoto supported AnGes in Clinical Development and Project Management. She started her career in pharmaceutical industry at Roche, Japan, where she served as a clinical scientist and was involved global clinical development in Japan, US and the EU.
Dr. Tanimoto received her MD from Toyama Medical & Pharmaceutical University, Japan, MBA from McGill University, MPH from National Institute of Public Health and PhD from Nippon Medical School. Fellow of the Japanese Society of Internal Medicine.
Terry joined MTG in 2014 and currently is acting executive vice president of clinical oncology. Previously, Terry served as Vice President, BioOncology Medical Affairs at Genentech since 2009. He joined at SGX Pharmaceuticals in 2006 as a Chief Medical Officer and Vice President, Development. Prior to that, he served as Vice President and Head of Oncology in Aventis and Sanofi-Aventis from 2002 to 2006. Before that, he held various positions at ILEX Oncology, British Biotech, Zeneca, and Eli Lilly. Terry received an M.D. degree from Godfrey Huggins School of Medicine and Master of Medicine from University of Natal.